Showing 1 - 10 of 1,232
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10009492625
Persistent link: https://www.econbiz.de/10013360312
Persistent link: https://www.econbiz.de/10003193758
Persistent link: https://www.econbiz.de/10002113607
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
Persistent link: https://www.econbiz.de/10012649390
We evaluate the impact of government mandated proof of vaccination requirements for access to public venues and non-essential businesses on COVID-19 vaccine uptake. We find that the announcement of a mandate is associated with a rapid and significant surge in new vaccinations (more than 60%...
Persistent link: https://www.econbiz.de/10012795392
Persistent link: https://www.econbiz.de/10003972551
Persistent link: https://www.econbiz.de/10009230280